Results 31 to 40 of about 728 (161)

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.

JACC: Heart Failure
BACKGROUND Long-term safety and efficacy data for aficamten in symptomatic obstructive hypertrophic cardiomyopathy are needed. OBJECTIVES This study aims to evaluate 48-week experience from the ongoing FOREST-HCM (A Follow-Up, Open-Label, Research ...
S. Saberi, T. Abraham, L. Choudhury, R. Barriales-Villa, P. Elliott, M. Nassif, A. Oręziak, A. Owens, A. Tower-Rader, F. Rader, P. García-Pavía, I. Olivotto, C. Coats, M. Fifer, M. Sherrid, Scott D. Solomon, Hugh Watkins, S. Heitner, D. Jacoby, S. Kupfer, F. Malik, C. Melloni, L. Meng, Jenny Wei, M. Maron, A. Masri   +25 more
semanticscholar   +2 more sources

Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis [PDF]

Archives of Medical Science: Atherosclerotic Diseases
Introduction Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with significant morbidity and mortality. Cardiac myosin inhibitors (MIs), including mavacamten and aficamten, offer a novel therapeutic approach for HCM ...
Mohammad Hazique, Sameer Lohana, Sunam Kafle, Jasgit Bhinder, Kunal N. Patel, Jawad Basit, Abdul Rasheed Bahar, Jared Kvapil, M. Chadi Alraies   +8 more
doaj   +2 more sources

Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. [PDF]

Circ Heart Fail
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality in children, but treatment options are limited. Aficamten, a next-in-class cardiac myosin inhibitor, directly targets the hypercontractility underlying HCM ...
Kaski JP, Kantor PF, Nakano SJ, Olivotto I, Russell MW, Godown J, Chiu M, German P, Heitner SB, Jacoby DL, Kupfer S, Lutz J, Maharao N, Malik FI, Melloni C, Nieto Morales PF, Simkins T, Wei J, Ho CY, CEDAR-HCM Investigators.   +19 more
europepmc   +2 more sources

Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic‐Cardiodynamic Modeling to Support Safety and Efficacy

CPT: Pharmacometrics & Systems Pharmacology
In the phase 3 study SEQUOIA‐HCM (NCT05186818), aficamten, a next‐in‐class cardiac myosin inhibitor, was safe and efficacious in participants with obstructive hypertrophic cardiomyopathy (oHCM). Using pharmacokinetics/pharmacodynamics (PKPD) modeling, we
Justin D. Lutz, Russ Wada, Daniel L. Jacoby, Stephen B. Heitner, Stuart Kupfer, Polina German   +5 more
doaj   +2 more sources

A plain language summary of the SEQUOIA-HCM study: aficamten for symptomatic obstructive hypertrophic cardiomyopathy. [PDF]

Future Cardiol
Plain Language Summary What is this summary about? This summary explains the main findings from the SEQUOIA-HCM study, which was published in the New England Journal of Medicine.
Maron MS, Olivotto I, van Sinttruije M.
europepmc   +2 more sources

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy

Scientific Reports, 2023
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease in humans and cats and lacks efficacious pharmacologic interventions in the preclinical phase of disease.
Ashley N. Sharpe, Maureen S. Oldach, Victor N. Rivas, Joanna L. Kaplan, Ashley L. Walker, Samantha L. Kovacs, Darren T. Hwee, Peadar Cremin, Bradley P. Morgan, Fady I. Malik, Samantha P. Harris, Joshua A. Stern   +11 more
doaj   +5 more sources

A New Era in the Management of Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Hypertrophic cardiomyopathy (HCM) is a prevalent cardiac disease characterized by marked phenotypic variability. Recent advances in diagnosis and treatment have allowed a personalized approach to the treatment of this disease.
Perez-Asensio A, Llamas-Gomez H, Lara-Palomo A, Villar-Ruiz A, Jimenez-Mendez C, Palomino-Doza J.   +5 more
europepmc   +3 more sources

Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials [PDF]

Frontiers in Cardiovascular Medicine
IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM).
Anas Abunada, Madiha Shah, Ateesh Kumar, Syeda Lamiya Mir, Dinesh Kumar, Saboor Ahmed, Muhammad Tanzeel, Vikash Kumar, Aashish Meghjiani, Muhammad Basit Ali Siddiqui, Govinda Khatri, Aneesh Rai, Fnu Deepak, Ayush Kumar   +13 more
doaj   +2 more sources

Safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy: A 36‐week analysis from FOREST‐HCM

European Journal of Heart Failure, Volume 26, Issue 9, Page 1993-1998, September 2024.
The aim of this study was to report safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy (nHCM) over 36 weeks in the ongoing FOREST‐HCM trial.
A. Masri, R. Barriales-Villa, P. Elliott, M. Nassif, A. Oręziak, A. Owens, A. Tower-Rader, S. Heitner, S. Kupfer, F. Malik, C. Melloni, L. Meng, Jenny Wei, S. Saberi   +13 more
semanticscholar   +2 more sources

Hypertrophic Cardiomyopathy: Current Perspectives [PDF]

Reviews in Cardiovascular Medicine
Hypertrophic cardiomyopathy (HCM) is a multifaceted genetic disorder characterized by left ventricular hypertrophy (LVH) in the absence of alternative causes, with an estimated prevalence ranging from 1 in 200 to 1 in 500 individuals. Since HCM was first
Dhruvil Patel, Ruchika Bhargav, Aliaa Mousa, Sabahat Bokhari   +3 more
doaj   +2 more sources